Detection of Heterogeneity in the Treatment of Atopic Dermatitis with T2-Specific Agents

Atopic dermatitis (AD) is a complex and heterogeneous chronic inflammatory dermatosis with significant individual differences in pathological mechanisms and treatment response. In recent years, the use of T2-specific drugs in the treatment of AD has attracted widespread attention, but the treatment response varies widely among patients. This review focuses on the heterogeneity of therapeutic responses of T2-specific drugs in patients with atopic dermatitis. By systematically combing relevant studies in recent years, this paper summarises a variety of methods for detecting patient heterogeneity, including clinical data-based analysis tools and biomarker detection techniques. The literature suggests that clinical indicators such as baseline lung function, acute exacerbation (AE) frequency, oral glucocorticoid use, and eosinophil count play an important role in the assessment of heterogeneity. This paper further discusses the impact of individual differences on T2-specific drug efficacy and points out the limitations of current studies and directions for future research, especially potential applications in the field of personalised therapy. The results aim to facilitate the optimisation of precision treatments for atopic dermatitis and contribute to the further investigation of heterogeneity detection tools.